Skip to main content

Table 1 Baseline characteristics of participants at trial entry: ITT population

From: S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial

 

Variable

SCCR (n = 20)

CCR (n = 20)

P value

Age, yrs: mean (SD)

 

59.6 (19.3)

60.4 (20.1)

0.90

Race

Asian (Chinese)

20 (100.0%)

20 (100.0%)

1.00

Sex

 

Males

15 (75.0%)

14 (70.0%)

0.72

 

Females

5 (25.0%)

6 (30.0%)

0.72

Performance status

 

0

13 (65.0%)

12 (60.0%)

0.74

 

1

7 (35.0%)

8 (40.0%)

0.74

Histology

 

Adenocarcinoma

9 (45.0%)

10 (50.0%)

0.75

 

Squamous cellcarcinoma

7 (35.0%)

5 (25.0%)

0.49

 

Large cell carcinoma

4 (20.0%)

5 (25.0%)

0.71

Stage of disease

 

IIIA

16 (80.0%)

14 (70.0%)

0.47

 

IIIB

4 (20.0%)

6 (30.0%)

0.47

Primary site

 

Upper lobe

13 (65.0%)

15 (75.0%)

0.49

 

Middle/lower lobe

7 (35.0%)

5 (25.0%)

0.49

  1. Note: ITT, intent-to-treat; SCCR, S-1, cisplatin and concurrent thoracic radiation; CCR, cisplatin and concurrent thoracic radiation; yrs, years; SD, standard deviation.